Background: Our preliminary results showed that tenosynovial changes and decrease in grip strength are associated with the aromatase inhibitor-induced musculoskeletal syndrome (AIMSS). Here, we report the final results and assess the relationship between grip strength and body mass index (BMI).
introduction
The third-generation aromatase inhibitors (AIs) anastrozole, letrozole and exemestane have become an established component of treatment of postmenopausal hormoneresponsive breast cancer. There is superiority over tamoxifen in terms of both disease-free survival and toxicity profile, with a lower incidence of thromboembolism and endometrial cancer [1] [2] [3] [4] [5] [6] . The long-term use of AIs in the metastatic, adjuvant and probably also preventive setting will increase worldwide [7] [8] [9] .
Aromatase inhibitor-induced musculoskeletal syndrome (AIMSS) was first reported in the metastatic setting [10] . Recent trials comparing AIs with tamoxifen or placebo recognized AIMSS as a problem, but incidence rates were underestimated [11] [12] [13] . Three features of AIMSS (arthritis, arthralgia, myalgia) were each significantly more frequent with letrozole than with placebo in tamoxifen-pretreated patients in the MA. 17 study [14] . In the Intergroup Exemestane Study, the adjuvant switch trial with exemestane, arthralgia was worse and carpal tunnel syndrome (CTS) was nine times more prevalent in patients who switched after 2-3 years from tamoxifen to exemestane compared with those treated with 5 years of tamoxifen [3] . Similarly, CTS was 3.5 times more frequent in women receiving anastrozole than in women receiving tamoxifen on the Arimidex, Tamoxifen, Alone or in Combination (ATAC) clinical trial [15] . AIMSS is now better defined and includes, in addition to arthralgia or joint pain, also musculoskeletal pain, CTS, joint stiffness and paresthesia. Therefore, in daily clinical practice, up to half of our patients experience AIMSS, some of whom report worsening of preexisting symptoms. This hampers compliance and eventually, one of four patients abandons treatment due to incapacitating symptoms that can severely impact daily functioning and quality of life [16] [17] [18] [19] [20] .
Although the anatomic correlate of AIMSS has been thoroughly evaluated with plain X-rays [21] , magnetic resonance imaging (MRI) [22] , ultrasound [23, 24] and electromyography [23] , the pathogenesis remains unknown. There is inconsistency regarding AI-induced changes in inflammatory mediators previously associated with estrogen signaling, but pretreatment cytokine levels may predict AIMSS [25, 26] . It is indeed important to identify patients at risk for AIMSS not only to clarify its pathogenesis but also to suggest an effective treatment as this condition remains difficult to manage. Some approaches like vitamin D supplementation, acupuncture and diuretics look promising [27] [28] [29] [30] . Reports on the effect of weight or body mass index (BMI) on AIMSS are conflicting but in the ATAC trial, obese women (BMI > 30 kg/m 2 ) were more likely to report joint symptoms (37.2%) than women with a BMI of 25-30 kg/m 2 (31.3%) and women with a BMI < 25 kg/m 2 (31.0%) [31] . Others have also demonstrated a significant association between a high BMI and joint pain as during the menopausal transition [32] .
We prospectively assessed changes in rheumatologic symptoms (morning stiffness and grip strength) and in MRI findings (tenosynovial abnormalities and intra-articular fluid) in AI users. Interim results have previously been reported from the first 17 patients [22] . In addition, we hypothesized that patients with either high or low pretreatment BMI would have a greater decrease in grip strength than those with intermediate BMI, so we retrospectively assessed the association between BMI and change in grip strength. Based on our findings, we have developed a novel hypothesis related to the etiology of AIMSS.
patients and methods

design, setting and participants
We conducted a prospective single-center cohort study in the University Hospitals Leuven (Leuven, Belgium). Consecutive postmenopausal women with early breast cancer scheduled to start first-line adjuvant endocrine therapy with any of the third-generation AIs (anastrozole, letrozole, or exemestane) or tamoxifen were included in this study. The decision to start an AI or tamoxifen was based on our institution's in-house protocol for use of either therapy; there was no self-selection of patients based on age or underlying joint symptoms. Patients (n = 33) were recruited from May 2006 to July 2008. Since this paper is focused on AI-induced problems and only a minority of patients received tamoxifen, results for the tamoxifen patients are only reported briefly.
measurements and study variables
The methods were reported in the initial paper [22] . Briefly, patients completed demographic data and a rheumatologic history questionnaire. At baseline, weight and height were assessed to calculate pretreatment BMI. A single-blinded rheumatologist carried out clinical examination of both hands, which included careful assessment of joint and tendon abnormalities and functional evaluation by a hand grip test. MRI of both hands and wrists was carried out in each patient. All images were interpreted by the same blinded experienced musculoskeletal radiologist. Both clinical and radiologic follow-up investigations were repeated after 6 months of therapy or earlier when patients considered stopping treatment prematurely because of severe joint complaints.
MRI results are reported as number of images that showed the pathological abnormality over the total of images taken (there is one image for each hand and thus two images per patient). The repeat rheumatologic examination and MRI at 6 months took into account the baseline findings. The results of the rheumatologic examination after 6 months therapy are reported as either a new onset of symptoms or worsening of a preexisting symptom from baseline for each patient. Scores for morning stiffness could be 21 (improvement of preexisting findings or disappearance), 0 (no change) or 1 (worsening of preexisting findings or new onset). Tenosynovial changes were defined as an increase in the amount of fluid in the tendon sheath or thickening and enhancement of the tendon sheaths. For tenosynovial abnormalities and intra-articular fluid, the scores for each hand were as per the rheumatological examination (21, 0, 1). Also, a combined score was constructed by summing the scores of both hands. This score could equal 22 (improvement for both hands), 21 (improvement for one hand, no change for the other), 0 (no change for both hands or improvement for one hand and worsening for the other), +1 (worsening for one hand, no change for the other) or +2 (worsening for both hands). Changes in grip strength were expressed as the percentage change versus baseline.
The study was conducted according to the guidelines for clinical studies described in the Declaration of Helsinki [33] . The protocol was approved by the Ethical Committee for Clinical Studies of the University Hospitals Leuven, Belgium, before commencement of the study and all participants provided written informed consent.
study end points
The primary end point was the change from baseline in tenosynovial abnormalities on MRI. Secondary end points were changes from baseline for morning stiffness, grip strength and intra-articular fluid on MRI. An additional retrospective end point was the relationship between BMI and changes in grip strength.
statistical analysis
Changes in tenosynovial abnormalities, intra-articular fluid and morning stiffness were analyzed using percentages together with 95% confidence intervals (CIs) for multinomial proportions [34] and using the sign test. Changes in grip strength were analyzed by the median percentage change versus baseline with a 95% CI based on the binomial distribution [35] and the sign test. For tamoxifen patients, the results were listed without constructing CI or applying the sign test. The effect of BMI on the percentage change in grip strength for AI users was analyzed using fixedeffects repeated measurements regression analysis. The repeated measurements represent the presence of two grip strength results per patient, one from each hand. We therefore have twice as many data points as patients. Predictors used in the model were hand (to account for the repeated measurements), BMI, age, changes in tenosynovial abnormalities per hand (21, 0 or 1) and changes in intra-articular fluid per hand (21, 0 or 1). Special attention was given to the hypothesized quadratic effect of BMI, and for age and BMI, possible nonlinearities were explored using local regression (loess). To investigate model assumptions and the influence of data point on the model fit, influence diagnostics were examined, such as studentized residuals, Cook's D, the covariance ratio, and the normal quantile plot [36] . results baseline demographic and medical characteristics Thirty-three patients completed all the planned investigations and were included in this report. Of these patients, 27 were treated with an AI (letrozole, n = 8; exemestane, n = 12; anastrozole, n = 7) and 6 with tamoxifen. Baseline demographic and medical characteristics are described in original article Annals of Oncology Over half of the postmenopausal breast cancer patients scheduled to receive adjuvant endocrine therapy had some form of preexisting musculoskeletal disorder. On baseline MRI, there was fluid accumulation seen in the joints of nine AI users and in two of the tamoxifen patients. Tenosynovial abnormalities were seen in seven of the AI users and in two of the tamoxifen patients.
MRI changes after 6 months of antihormonal therapy
After 6 months, we observed that tenosynovial abnormalities and amount of intra-articular fluid remained stable or had worsened relative to baseline in all patients (Table 2 ). On MRI follow-up, 20 AI patients (74%, 95% CI 51% to 89%) had worsening of preexisting changes or new onset of any pathological abnormality in joints or tendons, 13 of them in both hands. Of the tamoxifen patients with valid MRI data, three had no changes and two worsened in both hands.
Regarding intra-articular fluid, 56% (95% CI 34% to 75%) of the AI users had an increase in intra-articular fluid. In the tamoxifen-treated patients, two patients had an increase in intra-articular fluid in one hand, whereas one patient worsened in both hands. For both tenosynovial abnormalities and intraarticular fluid, no one improved relative to baseline. The P value of the sign test to test for a change from baseline was <0.001 for both MRI measurements. There were no differences in findings when results were analyzed by baseline findings. change in grip strength and morning stiffness from baseline to 6 months antihormonal therapy Changes in morning stiffness are presented in Table 3 . Six AI patients (22%, 95% CI 9% to 45%) experienced increased morning stiffness from baseline whereas no one improved. The P value of the sign test was 0.031. None of the tamoxifen patients experienced increased or new-onset morning stiffness.
Grip strength in the left and right hands decreased after 6 months of antihormonal therapy (Table 4 ). There is a tendency to have more strength in the right hand (which is more often the dominant hand; Table 1 ) and to have a larger decrease in strength for this hand. AI patients experienced a median decrease of 8% relative to baseline for the left hand (range 220.5% to 22%) and a median reduction of 11.4% relative to baseline for P value for sign test to test whether there is a significant difference from 0 in the change in tenosynovial thickening for AI users (<0.001) and in intraarticular fluid for AI users (<0.001). Score: 22, improvement for both hands; 21, improvement for one hand, no change for the other; 0, no change for both hands or improvement for one hand and worsening for the other; +1, worsening for one hand, no change for the other; and +2, worsening for both hands.
a One patient was excluded due to invalid MRI data. MRI, magnetic resonance imaging; AI, aromatase inhibitor; Tam, tamoxifen; CI, confidence interval. relationship between BMI and grip strength for AI users
Change in grip strength was predicted using tenosynovial changes, fluid changes, age and BMI. There was one patient with BMI 45 kg/m 2 whose data had an enormous influence on the model fit. Because this value was a significant outlier (second largest BMI was 32.9 kg/m 2 ), we decided to omit this patient from the analysis. As shown in Table 5 , the quadratic effect of BMI was a predictor of grip strength change (parameter estimate 20.68, standard error 0.21, P = 0.003). The BMI values of the patients included in the analysis range between 18 and 33 kg/m 2 . This effect is visualized in Figure 1 for a random hand (either right or left) of an 'average' patient (i.e. 64 years, worsened tenosynovial abnormalities, unchanged intra-articular fluid) across a range of BMIs. When BMI increases from 18 to 25, the expected percentage decrease in grip strength becomes smaller. When BMI increases from 25 to 33, the expected decrease becomes larger again. A nonparametric regression analysis using local regression (loess) that included the highly influential case supported the quadratic effect of BMI between 18 and 33 kg/m 2 .
discussion
Results of this study for all patients are consistent with our previously reported preliminary results [22] . Serial assessment, rheumatologic examination and MRI of hand and wrist after 6 months therapy showed a marked worsening of all parameters compared with baseline. The tenosynovium thickened substantially in AI users and the amount of intra-articular fluid increased. Our finding regarding a high BMI as a predictor for AI-induced loss of grip strength is consistent with findings reported by Crew et al. and Sestak et al. [20, 29] . A high BMI has previously been associated with aches and stiff joints in a population-based prospective study of perimenopausal Australian-born women, menstruating at baseline and interviewed annually over 8 years to test the effect of decreasing estrogens on arthralgia [32] . However, we also found an association between AI-induced loss of grip strength and a low BMI. Although Crew et al. [20] only reported high BMI as a risk factor for AIMSS in a cross-sectional survey of consecutive postmenopausal women receiving adjuvant AI therapy for early-stage hormone-sensitive breast cancer, joint pain and stiffness were also more frequent in women with a low BMI as compared with women with a normal BMI; this increase was significant for joint pain but not for stiffness. This is in line with our findings of a functional loss in women with extremes in BMI. We previously discussed the scoring system we adapted for reporting changes in morning stiffness, MRI images and hand grip strength [22] . Tenosynovial and articular changes as seen on MRI identify the anatomic substrate for the hand pain and disability that characterize AIMSS and the increased incidence of CTS. The strength of our prospective study is that each original article Annals of Oncology patient served as her own control. Therefore, our results may be considered as unbiased since we report changes induced by treatment rather than mere prevalence of symptoms or radiologic findings, which are likely to be biased by the high background of nonspecific muscle and joint aches in postmenopausal women affected by breast cancer.
A potential weakness in our study design was MRI reproducibility as we lack data on inter-and intraobserver variability in image interpretation. However, all images were assessed by the same musculoskeletal radiologist who was blinded to the treatment patients were receiving and to the other clinical data.
It has been hypothesized that AIMSS is caused by profound estrogen deprivation induced by the potent third-generation AIs. There are numerous reports exploring a possible link between estrogen deprivation, joint disorders and pain. Because estrogen can exert a direct antinociceptive effect on the central nervous system [37] [38] [39] [40] , one may hypothesize that estrogen deprivation could lead to enhanced pain sensation. The absence of circulating estrogens at the level of estrogen receptors in joint tissue may also induce as yet unknown biochemical and pathophysiological changes at peripheral sites, leading to debilitating joint pain. It is clear that other mechanisms play an important role in AIMSS.
The nonlinear relationship between BMI and AI-induced loss of grip strength suggests an underlying biological process. Circulating insulin-like growth factor-I (IGF-I) is one of several health-related processes with a nonlinear relationship with BMI [41] [42] [43] [44] . Individuals with a BMI of 26-27 kg/m 2 have a higher IGF-I concentration compared with those with either a lower or a higher BMI [45] [46] [47] [48] [49] . IGF-I is a potential candidate to be involved in AIMSS for different reasons. Increases in IGF-I by treatment with growth hormone for prevention or treatment of effects of aging worsen or induce arthralgia and CTS [50] . IGF-I is regulated by circulating estrogens; hormone replacement therapy, tamoxifen and AI have all been shown to affect circulating IGF-I concentrations [51] . Lowering estrogen levels by switching from oral to transdermal hormone replacement therapy increases IGF-I and induces joint pains and arthralgia [52] . Tamoxifen lowers IGF-I in a dosedependent way as a result of its estrogenic activity on different target systems [53, 54] . Tamoxifen is efficacious in treating arthralgia from Dupuytren syndrome [55] . AI use in breast cancer increases circulating IGF-I levels [56] [57] [58] [59] . In a randomized controlled trial comparing tamoxifen with the AI vorozole, IGF-1 levels fell significantly in the tamoxifen group, whereas vorozole patients showed a nonsignificant increase and the difference between groups was significant [60] . It is therefore not surprising that symptomatic arthralgia is more likely in women switching from tamoxifen to an AI compared with women starting with an AI [4, 15] .
Our findings are hypothesis generating. Proof of principle for a role of IGF-I in AIMSS may come from ongoing studies using IGF receptor blockers to improve efficacy from AIs. We are currently prospectively testing whether AI-induced changes from baseline in circulating IGF-I are related to AIMSS. Women with extremes in BMI may be more affected by this increase since baseline levels in this population are low. If this hypothesis is confirmed, this could potentially lead to additional options for therapy of AIMSS. For example, Lombardi et al. [61] have recently shown that somatostatin is useful to treat symptomatic patients with elevated IGF-I levels including those with arthralgia.
In conclusion, we have shown that after 6 months of antiestrogen therapy, patients treated with an AI experience new onset or worsening of preexisting musculoskeletal symptoms. AI users developed a significant decrease in grip strength and an increase in tenosynovial changes and intraarticular fluid on MRI. Furthermore, grip strength decreased more strongly for patients with a high BMI (30 kg/m 2 ) or a low BMI (20 kg/m 2 ). These findings suggest a potential role for IGF-I in the development of AIMSS. 
